Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) shares passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.08 and traded as high as $0.0968. Inhibitor Therapeutics shares last traded at $0.0968, with a volume of 2,000 shares traded.
Inhibitor Therapeutics Price Performance
The company has a market cap of $16.82 million, a PE ratio of -9.68 and a beta of -0.67. The stock’s 50-day moving average is $0.09 and its 200 day moving average is $0.08.
Inhibitor Therapeutics Company Profile
Inhibitor Therapeutics, Inc (OTCMKTS:INTI) is a clinical-stage pharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s approach has centered on evaluating established compounds for potential use in oncology.
Its primary development program has involved itraconazole, an antifungal medication that is being investigated for potential anticancer applications. Inhibitor Therapeutics has studied itraconazole in connection with cancers including prostate cancer and non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Inhibitor Therapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
